Can you take Clofazimine with Tecovirimat?
1 drug interaction and 6 additional warnings found for the following 2 drugs:
- clofazimine
- tecovirimat
Drug interactions
Minor drug interactions
Minor:
clofazimine tecovirimat
Applies to: clofazimine and tecovirimat
The potential for additive effects on the QT interval during coadministration of tecovirimat with QT-prolonging drugs has not been established. U.S. product labeling states that tecovirimat does not prolong the QT interval to any clinically relevant extent at the anticipated therapeutic exposure. In a double-blind, placebo- and positive-controlled, randomized, crossover ECG assessment study described in Canadian product labeling, 48 healthy subjects received a single supratherapeutic dose of tecovirimat 1000 mg. The maximum difference from placebo in mean change from baseline QTcF was 5.1 ms at 4 hours after dosing. Therapeutic plasma concentrations of tecovirimat metabolites were not achieved in this study, limiting its assessment of the effects at therapeutic metabolite exposure.
The information above is from our professional interaction data. Consumer information is not available for this interaction.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
tecovirimat Food/Lifestyle
Applies to: tecovirimat
Food may increase the absorption of tecovirimat when taken orally, which may lead to higher blood levels of the medication.
You should take oral preparations of tecovirimat within 30 minutes after a full meal containing moderate or high fat (approximately 600 calories and 25 g of fat) with 6 to 8 ounces of water.
Disease interactions
5 potential interactions Applies to: 5 conditions, including Diarrhea, Inflammatory Bowel Disease, Liver Disease, Renal Dysfunction, and Smallpox.
Diarrhea
Moderate:
clofazimine
Clofazimine has a moderate potential interaction with Diarrhea.
The use of clofazimine has been associated with severe abdominal symptoms including splenic infarction, bowel obstruction, and GI bleeding. Death has been reported following severe abdominal symptoms. Crystalline deposits have been found in the intestinal mucosa, liver, gallbladder, bile, spleen, adrenals, subcutaneous fat, mesenteric lymph nodes, muscles, bone and skin. Clofazimine should be administered cautiously in patients with GI problems such as abdominal pain and diarrhea.
Inflammatory Bowel Disease
Moderate:
clofazimine
Clofazimine has a moderate potential interaction with Inflammatory Bowel Disease.
The use of clofazimine has been associated with severe abdominal symptoms including splenic infarction, bowel obstruction, and GI bleeding. Death has been reported following severe abdominal symptoms. Crystalline deposits have been found in the intestinal mucosa, liver, gallbladder, bile, spleen, adrenals, subcutaneous fat, mesenteric lymph nodes, muscles, bone and skin. Clofazimine should be administered cautiously in patients with GI problems such as abdominal pain and diarrhea.
Liver Disease
Moderate:
clofazimine
Clofazimine has a moderate potential interaction with Liver Disease.
Use of clofazimine should be avoided in patients with hepatic dysfunction (Child-Pugh A, B, or C).
Renal Dysfunction
Moderate:
clofazimine
Clofazimine has a moderate potential interaction with Renal Dysfunction.
Clofazimine should be used with caution in patients with severe renal dysfunction. No dose adjustments are recommended in patients with mild to moderate renal dysfunction.
Smallpox
Major:
tecovirimat
Tecovirimat has a major potential interaction with Smallpox.
Tecovirimat injection is contraindicated in patients with severe renal dysfunction (CrCl below 30 mL/min).
Report options
More resources
clofazimine
A total of 390 drugs are known to interact with clofazimine.
- Clofazimine is in the drug class leprostatics.
- Clofazimine is used to treat the following conditions:
tecovirimat
A total of 537 drugs are known to interact with tecovirimat.
- Tecovirimat is in the drug class miscellaneous antivirals.
- Tecovirimat is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.